Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NBIO 8,000,000 float
$NBIO keep an eye on this one fellas. When the volume comes it moves on air.
2 Cancer drugs in development
No debt
Low burn rate
Clean Level 2
No dilution
No convertables
8,000,000 float
$NBIO .49.5
$25,000 in dollar volume and this rockets over a buck. Paper thin boys.
$NBIO .49.5
$25,000 in dollar volume and this rockets over a buck. Paper thin boys.
NBIO ***Alert*** $NBIO ***Pounding The Table***$NBIO
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
High Alert!!!
$NBIO ***Alert*** $NBIO ***Pounding The Table***$NBIO
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
High Alert!!!
$NBIO***Read Below***
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
High Alert
$NBIO***Read Below***
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
High Alert
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
$NBIO...100% Absolute real undervalued company with FDA news on the way.
8,000,000 share float, tight and wound. Ten grand in dollar volume and this shoots over a dollar.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO...100% Absolute real undervalued company with FDA news on the way.
8,000,000 share float, tight and wound. Ten grand in dollar volume and this shoots over a dollar.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO news coming!
$NBIO news coming!
$NBIO on high alert this week. Primed for the next leg up. Anything under a buck is the deal of a life tone IMO. Rock solid DD. Real company, real drugs, no dilutions, moves on air.
8,000,000 float locked up tight.
No sellers.
$NBIO on high alert this week. Primed for the next leg up. Anything under a buck is the deal of a life tone IMO. Rock solid DD. Real company, real drugs, no dilutions, moves on air.
8,000,000 float locked up tight.
No sellers.
$NBIO 8,410,110 FLOAT
No Convertibles
No Debt
Clean level 2's
28,000,000 Shares Outstanding
19,000,000 Restricted
8,410,110 Float
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO...100% Absolute real undervalued company with FDA news on the way.
8,000,000 share float, tight and wound. Ten grand in dollar volume and this shoots over a dollar.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO...100% Absolute real undervalued company with FDA news on the way.
8,000,000 share float, tight and wound. Ten grand in dollar volume and this shoots over a dollar.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO Share Structure: Clean L2, No Dilution, No Debt, No Convertible Note
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO Share Structure: Clean L2, No Dilution, No Debt, No Convertible Note
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO on high alert.
8,000,000 share float.
$NBIO keep this on your watch list. Any news, any volume... and it will fly.
$NBIO virtually no sellers. No volume ever gets served at the bid. Anything under a dollar is a gift.
No Dilution
No Debt
No Convertibles
Clean Level 2
2 Drugs nearing FDA
8,000,000 Float
This is an absolute no brainier for me, give it a look.
$NBIO virtually no sellers. No volume ever gets served at the bid. Anything under a dollar is a gift.
No Dilution
No Debt
No Convertibles
Clean Level 2
2 Drugs nearing FDA
8,000,000 Float
This is an absolute no brainier for me, give it a look.
$NBIO... This is the real deal fellas, news coming, zero dilution, zero debt, 2 drugs far along the pipeline, and no convertible debt on the books. The stock moves on air. $5.00 by end of the year.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO Share Structure: Clean L2, No Dilution, No Debt, No Convertible Note
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO Share Structure: Clean L2, No Dilution, No Debt, No Convertible Note
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
$NBIO...100% Absolute real undervalued company with FDA news on the way.
8,000,000 share float, tight and wound. Ten grand in dollar volume and this shoots over a dollar.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO 8,410,110 FLOAT
No Convertibles
No Debt
Clean level 2's
28,000,000 Shares Outstanding
19,000,000 Restricted
8,410,110 Float
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO is ready. I am amazed people are not on this play. Check out the DD and info on the board. This is a real company.
No Promo
No Convertibles
No Debt
Clean level 2's
28,000,000 Shares Outstanding
19,000,000 Restricted
8,410,110 Float
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO is ready. I am amazed people are not on this play. Check out the DD and info on the board. This is a real company.
No Promo
No Convertibles
No Debt
Clean level 2's
28,000,000 Shares Outstanding
19,000,000 Restricted
8,410,110 Float
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
Take a look at $NBIO. Prime for the taking.
$NBIO is completely under the radar and undervalued.
No Promo
No Convertibles
No Debt
Clean level 2's
28,000,000 Shares Outstanding
19,000,000 Restricted
8,410,110 Float
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
https://investorshub.advfn.com/Nascent-Biotech-Inc-NBIO-14780/
Starting to take shape. Its going to be a great long term hold.
Nascent Biotech $NBIO Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
Nascent Biotech $NBIO Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO early and often.
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.